[go: up one dir, main page]

WO2009069151A3 - Controlled release composition - Google Patents

Controlled release composition Download PDF

Info

Publication number
WO2009069151A3
WO2009069151A3 PCT/IN2008/000793 IN2008000793W WO2009069151A3 WO 2009069151 A3 WO2009069151 A3 WO 2009069151A3 IN 2008000793 W IN2008000793 W IN 2008000793W WO 2009069151 A3 WO2009069151 A3 WO 2009069151A3
Authority
WO
WIPO (PCT)
Prior art keywords
release composition
controlled release
sustained release
oral sustained
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2008/000793
Other languages
French (fr)
Other versions
WO2009069151A2 (en
Inventor
Akhilesh Ashok Dixit
Ashis Shankerlal Mehta
Sanjay Deshraj Verma
Abhijit Mukund Deshmukh
Kiran Kumar Subba Raja Madallapalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2009069151A2 publication Critical patent/WO2009069151A2/en
Publication of WO2009069151A3 publication Critical patent/WO2009069151A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of sorbitol and/or sucrose esters as a sustained release carrier to provide oral sustained release composition. The invention further relates to the process of preparation of such oral sustained release pharmaceutical compositions.
PCT/IN2008/000793 2007-11-30 2008-11-28 Controlled release composition Ceased WO2009069151A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2860CH2007 2007-11-30
IN2860/CHE/2007 2007-11-30

Publications (2)

Publication Number Publication Date
WO2009069151A2 WO2009069151A2 (en) 2009-06-04
WO2009069151A3 true WO2009069151A3 (en) 2009-12-30

Family

ID=40679102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000793 Ceased WO2009069151A2 (en) 2007-11-30 2008-11-28 Controlled release composition

Country Status (1)

Country Link
WO (1) WO2009069151A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN111432807A (en) 2017-10-06 2020-07-17 铸造疗法股份有限公司 Implantable reservoir for controlled release of therapeutic agents
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
CN116942608B (en) * 2023-08-15 2025-08-22 沈阳药科大学 Amoxicillin injection for veterinary use and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259033A1 (en) * 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
WO2009069151A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
ZA200900347B (en) Preparation of pharmaceutical compositions
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
SI2318004T1 (en) Pharmaceutical compositions containing the crystalline form y of posaconazole
WO2007095116A3 (en) Glass compositions for protecting glass and methods of making and using thereof
MX2011012523A (en) Ketal esters of anhydropentitols and uses thereof.
IL218370A0 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen, processes for producing the same and uses thereof
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
TW200621313A (en) Pharmaceutical compositions
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2012009438A3 (en) Anti-appetite adhesive compositions
WO2010049449A3 (en) Novel salts of sunitinib
WO2009069151A3 (en) Controlled release composition
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
HRP20130447T1 (en) Pharmaceutical composition with prolonged release of octreotide acetate
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008154234A3 (en) Extended release formulation of nevirapine
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
ZA201102652B (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
ZA200800729B (en) A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it
WO2010023473A3 (en) Crystalline form of sunitinib and processes for its preparation
WO2007110765A3 (en) Processes for the preparation of octreotide

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08853912

Country of ref document: EP

Kind code of ref document: A2